Abstract
Rabies remains a major public health threat around the world. Once symptoms appear, there is no effective treatment to prevent death. In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glycoprotein (G) of rabies (PIV5-G) as a therapy for rabies virus infection: we have found that PIV5-G protected mice as late as 6 days after rabies virus infection. PIV5-G is a promising vaccine for prevention and treatment of rabies virus infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Antibodies, Viral / immunology
-
Gene Expression
-
Genetic Vectors / genetics*
-
Genetic Vectors / metabolism
-
Humans
-
Mice
-
Parainfluenza Virus 5 / genetics*
-
Parainfluenza Virus 5 / metabolism
-
Rabies / immunology
-
Rabies / prevention & control*
-
Rabies / virology
-
Rabies Vaccines / administration & dosage*
-
Rabies Vaccines / genetics
-
Rabies Vaccines / immunology
-
Rabies virus / genetics
-
Rabies virus / immunology*
-
Viral Envelope Proteins / administration & dosage*
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology
Substances
-
Antibodies, Viral
-
Rabies Vaccines
-
Viral Envelope Proteins